Research - Clinical Research - Multiple Sclerosis
|Grant Funded Current Research - Neurology
Grant Funded Past Research - Neurology
For questions about becoming involved with our multiple sclerosis studies, please
Andrea Korsnack, RN, Certified Clinical Research Coordinator * 419-383-3801 * firstname.lastname@example.org
The University of Toledo Multiple Sclerosis Clinic maintains clinical affiliation with the National Multiple Sclerosis Society (www.nationalMSsociety.org), and participates in NIH- and pharmaceutically supported clinical trials for the treatment of multiple sclerosis.
Current Clinical Trials:
- A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5 mg fingolimod (fty720) administered orally once daily in patients with multiple sclerosis; Sponsored by Novartis Pharmaceuticals
- A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis; Sponsored by Novartis Pharmaceuticals
- A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta; Sponsored by Sanofi
The University of Toledo participated in the following clinical trials (enrollment complete):
- CombiRx Trial: A multi-center, randomized, blinded study of Avonex® alone, Copaxone® alone, or a Combination® of both Avonex® and Copaxone® in subjects with relapsing-remitting multiple sclerosis who have never received disease modifying therapy (NIH; Mt. Sinai School of Medicine, New York, NY).
- A 24-month, double-blind, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg Fingolimod (FTY 720) administered once daily versus placebo in patients with relapsing-remitting multiple sclerosis (Novartis).
For updated information on multiple sclerosis clinical trials at the University of Toledo, search http://www.clinicaltrials.gov using the key words “multiple sclerosis AND Toledo.”
Basic science research:
- Additional projects include translational research collaborations to evaluate potential new treatments for MS in experimental autoimmune encephalomyelitis (EAE) with:
- Anthony Quinn, PhD, Associate Professor, Department of Biology (http://www.utoledo.edu/nsm/bio/research/quinn.html);
- Miles Hacker, PhD, Professor, Department of Pharmacology (http://www.utoledo.edu/pharmacy/depts/pharmacology/faculty-mhacker.html).
Kiraly A, Quinn A, Gunning W, Koffman B, Hacker M. "Treatment with a novel aza-anthrapyrazole prevents MOG-induced EAE" for the 15th annual meeting of ACTRIMS, San Antonio, Texas, June 5, 2010.
Koffman BM, Mutgi S, Crooks R, Khuder S, Herial NA. “Impact on oral health in multiple sclerosis and epilepsy: a neurology clinic survey” for the 24th annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), San Antonio, Texas, June 2-5, 2010.